[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-induced-dermatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-induced-dermatitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100647110","phase-2-superoxide-dismutase-skin-spray-for-the-prevention-of-acute-radiation-dermatitis-in-head-and-neck-cancer-100647110",false,"NCT07704372","Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer","Superoxide Dismutase Skin Spray for Reducing Acute Radiation Dermatitis in Patients With Head and Neck Cancer Undergoing Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n1. Histologically confirmed malignant tumors of the head and neck without distant metastasis.\n2. Scheduled to undergo either postoperative adjuvant radiotherapy or definitive radiotherapy, with or without concurrent chemotherapy.\n3. Age 18-80 years at the time of consent.\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n5. Signed informed consent form.\n6. Adequate cognitive and reading abilities to complete the questionnaire.\n\nExclusion Criteria:\n\n1. Pre-existing skin disease or open wounds in the irradiation field.\n2. Have a history of head and neck radiotherapy.\n3. Autoimmune or connective tissue disorders affecting skin.\n4. Known allergy to any component of study formulations.\n5. Any condition that, in the investigator's judgment, would interfere with study participation or outcome assessment.","ALL","18 Years","80 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To evaluate the efficacy and safety of superoxide dismutase skin spray for the reducing the acute radiation dermatitis in patients with head and neck malignancies undergoing radiotherapy.",[27],"Radiation-induced Dermatitis",[29,27,30],"Head & neck cancer","superoxide dismutase","NOT_YET_RECRUITING","2026-07-09",{"date":34,"type":35},"2026-07-15","ACTUAL",{"date":34,"type":21},{"date":38,"type":21},"2027-04-30",{"name":40,"class":41},"West China Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":5},"100620134","phase-2-topical-periplaneta-americana-derived-meilian-fuxin-liquid-for-radiation-dermatitis-100620134","NCT07353671","Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis","A Single-Center, Two-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of a Topical Periplaneta Americana-Derived Regenerative Solution (Meilian Fuxin Liquid) for the Treatment of Radiation Dermatitis","Inclusion Criteria:\n\n1. Age and Gender: Patients aged 18 to 80 years (inclusive of boundary values), regardless of gender.\n2. Diagnosis and Treatment: Patients with head and neck cancer (including nasopharyngeal carcinoma) who have been confirmed by histopathology and require radical radiotherapy or postoperative adjuvant radiotherapy.\n3. Performance Status: Patients with an ECOG Performance Status score of 0 to 2.\n4. Consent: Patients who voluntarily agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Prior Radiotherapy: Patients with a history of prior radiotherapy to the target area.\n2. Baseline Skin Condition: Baseline skin condition in the treatment area that may interfere with efficacy assessment (e.g., presence of open wounds, infection, rash, psoriasis, etc.).\n3. Systemic Diseases: Presence of connective tissue diseases or other systemic dermatoses.\n4. Known Allergies: Known allergy to any component of the investigational product (Meilian Fuxin Solution).\n5. Prior Clinical Research: Participation in other interventional clinical studies within the past 3 months and use of any investigational drugs or devices.\n6. Investigator Discretion: Subjects judged by the investigator to be unsuitable for participation in this clinical study.",{"count":51,"type":21},60,[24,53],"PHASE3","To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.",[27],[29,27,57],"Meilian Fuxin Solution","RECRUITING","2026-03-24",{"date":61,"type":35},"2026-03-25",{"date":63,"type":35},"2026-03-01",{"date":65,"type":21},"2027-06-30",{"name":40,"class":41}]